Scarica l'app Stockscreener
9.52
1.65%
-0.16
Dopo l'orario di chiusura:
9.33
-0.19
-2.00%
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas (NASDAQ:ARVN) Stock Price Up 5.5%What's Next? - MarketBeat
Is Arvinas Inc. trending in predictive chart modelsQuarterly Profit Review & Consistent Profit Trading Strategies - newser.com
What data driven models say about Arvinas Inc.’s futureJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
Chart overlay techniques for tracking Arvinas Inc.Quarterly Risk Review & AI Optimized Trading Strategy Guides - newser.com
Discipline and Rules-Based Execution in ARVN Response - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Downgraded by The Goldman Sachs Group to "Sell" - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap DownWhat's Next? - MarketBeat
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Goldman Sachs Downgrades Arvinas (ARVN) to 'Sell', Lowers Price Target | ARVN Stock News - GuruFocus
How to forecast Arvinas Inc. trends using time seriesJuly 2025 WrapUp & Fast Gain Swing Alerts - newser.com
Goldman Sachs Downgrades Arvinas to Sell From Neutral, Cuts Price Target to $6 From $8 - MarketScreener
Can Arvinas Inc. stock beat analyst upgradesWeekly Trade Analysis & Capital Efficiency Focused Ideas - newser.com
Goldman Sachs downgrades Arvinas stock to Sell on competitive risks By Investing.com - Investing.com Nigeria
Can Arvinas Inc. stock withstand economic slowdownQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
Published on: 2025-10-13 09:51:45 - newser.com
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress - The Manila Times
Arvinas, Inc. to Present New Patient-Reported Outcomes Data for Vepdegestrant at ESMO Congress 2025 - Quiver Quantitative
Arvinas to Present Data from the Vepdegestrant Clinical - GlobeNewswire
Phase 3 PRO data lead: Arvinas' vepdegestrant to be presented at ESMO Oct 19–20, 2025 in Berlin - Stock Titan
What MACD signals say about Arvinas Inc.Earnings Miss & High Conviction Buy Zone Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Full technical analysis of Arvinas Inc. stockTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook By Investing.com - Investing.com South Africa
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook - Investing.com
Arvinas Holding Company (ARVN) Receives a Hold from Bank of America Securities - The Globe and Mail
Piper Sandler raises Arvinas stock price target to $16 on LRRK2 degrader data - Investing.com
Arvinas Announces Positive Phase 1 Trial Results - TipRanks
Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell - MarketScreener
ARVN reports Phase 1 ARV-102 safety, CSF exposure and biomarker drops - Stock Titan
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Top Companies in Targeted Protein Degradation MarketBristol - openPR.com
Is Arvinas Inc. reversing from oversold territoryShort Setup & Weekly Chart Analysis and Guides - newser.com
Full Stock Market News from 2025-10-05 - Stock Titan
Arvinas (ARVN) Highlights Promising Phase 1 Trial Results for AR - GuruFocus
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials By Investing.com - Investing.com Nigeria
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials - Investing.com India
Arvinas, Inc. Reports Positive Phase 1 Trial Results for ARV-102 in Healthy Volunteers and Parkinson's Disease Patients - Quiver Quantitative
Arvinas Presents Late Breaking, Positive Phase 1 Clinical - GlobeNewswire
97% LRRK2 Reduction — Arvinas' ARV-102 Shows Strong PBMC Target Engagement and CSF Biomarker Modulation - Stock Titan
Will a bounce in Arvinas Inc. offer an exitJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com
Real time alert setup for Arvinas Inc. performanceJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Arvinas Inc. stock poised for growthQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Tools to monitor Arvinas Inc. recovery probabilityWeekly Loss Report & Real-Time Volume Analysis - newser.com
Can Arvinas' Brain-Penetrant PROTAC Deliver On Its Promise In Parkinson's Trials? - RTTNews
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):